AngioDynamics (NASDAQ:ANGO) Stock Passes Above 200-Day Moving Average – Should You Sell?

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.24 and traded as high as $11.00. AngioDynamics shares last traded at $10.85, with a volume of 481,880 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price target on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Price Performance

The stock has a market capitalization of $439.10 million, a PE ratio of -1.93 and a beta of 0.60. The business has a 50 day moving average price of $10.21 and a 200 day moving average price of $8.24.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the prior year, the firm posted ($0.05) earnings per share. The company’s quarterly revenue was down .1% on a year-over-year basis. On average, equities analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently modified their holdings of the business. Rhumbline Advisers boosted its position in shares of AngioDynamics by 1.7% during the fourth quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock valued at $554,000 after buying an additional 1,021 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in AngioDynamics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier’s stock worth $3,014,000 after purchasing an additional 2,270 shares during the last quarter. Quarry LP boosted its position in AngioDynamics by 40.9% in the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 2,471 shares during the last quarter. SG Americas Securities LLC boosted its position in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 2,832 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in AngioDynamics in the fourth quarter worth about $28,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.